This is a working overview of GLP-1 receptor agonist, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-07-30. Anything still debated is marked as such rather than presented as settled.
Degradation proceeds along several parallel routes. Deamidation of asparagine and glutamine residues generates charged variants that shift retention time in chromatographic analysis. Oxidation targets methionine and can be accelerated by trace metals or dissolved oxygen. Non-covalent aggregation produces dimers, oligomers, and larger species that are difficult to reverse. Isomerisation at aspartate residues is slower but measurable under thermal stress. The distribution among these pathways depends on pH, buffer composition, ionic strength, and the presence of excipients such as sugars or surfactants.
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 nm is the standard purity method, reported as area percent. Mass spectrometry, usually with electrospray ionisation, confirms identity and reveals covalent modifications. Size-exclusion chromatography quantifies aggregates and fragments. Peptide mapping after enzymatic digestion localises changes to specific sequence regions. Circular dichroism and infrared spectroscopy report on secondary structure, while light scattering tracks particle formation in liquid formulations. No single technique captures every quality attribute.
Quality control relies on pharmacopoeial monographs where they exist, combined with in-house specifications for identity, purity, water content, and counter-ion composition. Reference standards allow calibration across laboratories, although certified materials for every analogue are not universally obtainable. Batch records, chromatograms, and mass spectra form the documentation trail. Regulatory classification varies by jurisdiction and intended use, and research-grade material differs from pharmaceutical-grade material in testing scope. Analytical uncertainty is often expressed as relative standard deviation across replicate injections.
Semaglutide 是一种经结构修饰的胰高血糖素样肽-1 类似物，其主链与内源性 GLP-1(7-36) 约有百分之九十四的序列一致性。第 8 位丙氨酸被 α-氨基异丁酸取代，使二肽基肽酶-4 无法识别原有切割位点。第 34 位赖氨酸换为精氨酸，进一步降低酶解速率。第 26 位赖氨酸经间隔基连接一条含十八个碳的二酸脂肪链，该侧链赋予分子与血浆白蛋白结合的能力。
该分子作为 GLP-1 受体的选择性激动剂发挥作用，受体属于 B 类 G 蛋白偶联受体家族，激活后经 Gs 通路提升细胞内环腺苷酸水平。在胰腺 β 细胞，信号促进葡萄糖依赖性的胰岛素释放，血糖偏低时该作用明显减弱。在胰岛 α 细胞，胰高血糖素分泌受到抑制。中枢神经系统与胃肠道同样存在受体表达，相应信号参与食欲调节以及胃排空速率的降低。
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilised powder | visual inspection of solid |
| Solubility | Freely soluble in water, pH dependent | buffer choice affects clarity |
| Typical storage | -20 °C, desiccated, protected from light | solution form kept at 2-8 °C |
| Primary purity method | RP-HPLC with UV detection, 214-220 nm | reported as area percent |
| Identity confirmation | LC-ESI-MS, approximately 4114 Da | compared with theoretical mass |
Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
I wanted Glenn to know, so I went to his bedside and told him. I thought I saw a gleam in his eye, but the next day when I went to visit him he didn't remember seeing me. As a scientist, he had died when he had that stroke. Seaborg died two months later, on 25 February 1999. In March 1999, the same team replaced the 244Pu target with 242Pu to make other flerovium isotopes. Two atoms of flerovium were produced as a result, each alpha-decaying with a half-life of 5.5 s. They were assigned as 287Fl. This activity has not been seen again either, and it is unclear what nucleus was produced. It is possible that it was an isomer 287mFl or from electron capture by 287Fl, leading to 287Nh and 283Rg.
In 2023, a French court fined Servier €415m on appeal after finding it guilty of deception and manslaughter, as benfluorex's mechanism of action was fraudulently concealed, as Benfluorex was marketed after withdrawal of the any marketed fenfluramine anorectic (fenfluramine/phentermine, dexfenfluramine, clobenzorex, mefenorex, etc) because of their serious side effects like cardiac fibrosis and pulmonary hypertension (Benfluorex also shares the same side effects, but they were completely concealed, even though there were several reports of heart failure).
Adding to the speculation, it was revealed that Trump had made an hours-long visit to Walter Reed National Military Medical Center, his third visit within a year, where doctors administered what Trump says was his fourth Montreal Cognitive Assessment test. White House spokesperson Davis Ingle refuted concerns about Trump's health, stating the president had completed multiple engagements with open press slots for the end of the week, and labeled the concerns as "left-wing conspiracies". When questioned about his opinion of the president receiving four medical checkups since the beginning of his second term, Mehmet Oz told reporters that Trump was in perfect health and kept returning for checkups as he likes the results and aces the tests every visit. On June 3, during a House Foreign Affairs Committee Representative Ted Lieu (D-CA) questioned Secretary of State Marco Rubio over Trump's apparent sleeping in multiple public appearances such as Cabinet meetings. Rubio refuted the idea that Trump was sleeping, claiming that instead Trump does not sleep, and when presented with a video of Trump, appearing to sleep next to Rubio speaking about the Iran war Rubio doubled down claiming that Trump was not sleeping. Lieu expressed concern about how foreign leaders perceive Trump and the United States, and presented a foreign news segment video in which they mocked Trump "fighting sleep" during a Memorial Day ceremony. Trump also appeared to fall asleep at Game 3 of the 2026 NBA finals at Madison Square Garden.
Laboratory informatics is the specialized application of information technology aimed at optimizing and extending laboratory operations. It encompasses data acquisition (e.g. through sensors and hardware or voice), instrument interfacing, laboratory networking, data processing, specialized data management systems (such as a chromatography data system), a laboratory information management system, scientific data management (including data mining and data warehousing), and knowledge management (including the use of an electronic lab notebook). It has become more prevalent with the rise of other "informatics" disciplines such as bioinformatics, cheminformatics and health informatics. Several graduate programs are focused on some form of laboratory informatics, often with a clinical emphasis. A closely related - some consider subsuming - field is laboratory automation.
=== Clinical trials === Retatrutide has been studied in a phase 2 trial involving adults without diabetes but with obesity or preobesity (overweight). Retatrutide is also being evaluated in phase 3 clinical trials. Two trials in the phase 3 TRIUMPH program reached primary completion in April 2026: TRIUMPH-1, a master protocol in adults with obesity or overweight, and TRIUMPH-3, in participants with severe obesity and established cardiovascular disease. A substudy in adults with type 2 diabetes reported differences in total body fat mass between study groups at 36 weeks. Preclinical and biochemical studies describe receptor activity at GLP-1, GIP, and glucagon receptors. Reports on its development state that it was engineered for activity across these targets. Systematic reviews and meta-analyses of randomized controlled trials report that retatrutide produces substantial reductions in body weight in adults with obesity, with mean percentage weight loss typically between 15 and 24 percent over 48 to 72 weeks, depending on study protocols and populations. Adverse events are most commonly gastrointestinal symptoms such as nausea and diarrhea, with relatively low rates of study discontinuation and infrequent serious adverse events reported during trials. Safety assessments also indicate a low risk of hypoglycemia and no significant elevation in cardiovascular or hepatic adverse events in non-diabetic populations across published studies.
Sources: en.wikipedia.org
==== Instant-release absorption profiles and Tmax ==== Oxycodone can be administered orally, intravenously, via intravenous, intramuscular, or subcutaneous injection. Along with rectal, sublingual, buccal or intranasal drug delivery. The bioavailability of oral administration of oxycodone averages within a range of 60 to 87%, with rectal administration yielding the same results; Intranasal administration of oxycodone has a bioavailability of ~77%, the same half life as oral oxycodone, along with faster Tmax previously reported as 47% for nasal spray administration due to the solution in the study exceeding the 0.3- to 0.4-mL nasal mucosa limit. Buccal bioavailability ~55%, Tmax ~60 min. Sublingual bioavailability 20% (non alkalized) ~55% (alkalized) Tmax ~60 minutes. After a dose of conventional (immediate-release) oral oxycodone, the onset of action is 10 to 30 minutes, and peak plasma levels of the drug are attained within roughly 30 to 60 minutes; in contrast, after a dose of OxyContin (an oral controlled-release formulation), peak plasma levels of oxycodone occur in about three hours. Mean serum concentration of controlled-release oxycodone peaks at 78 ng/ml at 1 hour and drops to 20 ng/ml at 8 hours and under 10 ng/ml at 12 hours. The duration of instant-release oxycodone is 3 to 6 hours, although this can be variable depending on the individual.
Polatuzumab vedotin, sold under the brand name Polivy, is an antibody-drug conjugate medication used for the treatment of diffuse large B-cell lymphoma (cancer). Polatuzumab is an antibody that targets CD79b, and vedotin is an agent that inhibits cell division by blocking the polymerisation of tubulin. It was developed by the Genentech subsidiary of Roche. The most common side effects include low levels of white blood cells (neutropenia), platelets (thrombocytopenia) and red blood cells (anemia); nerve damage (peripheral neuropathy); fatigue; diarrhea; fever; decreased appetite; and pneumonia. Polatuzumab vedotin was approved for medical use in the United States in June 2019, in Australia in October 2019, in the European Union in January 2020, and in Canada in November 2020.
== Production == 5-HTP is produced from the amino acid tryptophan through the action of the enzyme tryptophan hydroxylase. Tryptophan hydroxylase is one of the biopterin-dependent aromatic amino acid hydroxylases. Production of 5-HTP is the rate-limiting step in 5-HT (serotonin) synthesis. 5-HTP is normally rapidly converted to 5-HT by amino acid decarboxylase.
The dioxide dissolves in acid to yield the trihydroxotellurium(IV) Te(OH)3+ ion; the red Te42+ and yellow-orange Te62+ ions form when tellurium is oxidized in fluorosulfuric acid (HSO3F), or liquid sulfur dioxide (SO2), respectively. It can form alloys with aluminium, silver, and tin. Tellurium shows fewer tendencies to anionic behaviour than ordinary nonmetals. Its solution chemistry is characterised by the formation of oxyanions. Tellurium generally forms compounds in which it has an oxidation state of −2, +4 or +6. The +4 state is the most stable. Tellurides of composition XxTey are easily formed with most other elements and represent the most common tellurium minerals. Nonstoichiometry is pervasive, especially with transition metals. Many tellurides can be regarded as metallic alloys. The increase in metallic character evident in tellurium, as compared to the lighter chalcogens, is further reflected in the reported formation of various other oxyacid salts, such as a basic selenate 2TeO2·SeO3 and an analogous perchlorate and periodate 2TeO2·HXO4. Tellurium forms a polymeric, amphoteric, glass-forming oxide TeO2. It is a "conditional" glass-forming oxide – it forms a glass with a very small amount of additive. Tellurium has an extensive organometallic chemistry (see Organotellurium chemistry).
Sources: en.wikipedia.org
The flowers emerge from an axillary cluster that has 12–20 buds. The flowers are greenish-yellow, with a diameter of 5 cm (2 in), and only have a slight scent. The flowers require pollination to set fruit, but open in the morning and usually fade in the rising temperatures of the same afternoon. Though each flower lasts only one day, the flowering of Vanilla planifolia takes place over a period of two months once a year. In its native lowland forest habitat flowering takes place in April and May, towards the end of the dry season. The plants are self-fertile, and pollination simply requires a transfer of pollen from anther to stigma, but they have a structure to prevent this from happening without intervention. In the wild, there is only around a 1% chance that any given vanilla flower will be successfully pollinated.
== Types of resins == Most typical ion-exchange resins are based on crosslinked polystyrene. The actual ion-exchanging sites are introduced after polymerisation. Additionally, in the case of polystyrene, crosslinking is introduced by copolymerisation of styrene and a few percent of divinylbenzene. Crosslinking decreases ion-exchange capacity of the resin and prolongs the time needed to accomplish the ion-exchange processes but improves the robustness of the resin. Particle size also influences the resin parameters; smaller particles have larger outer surface, but cause larger head loss in the column processes. Besides being made as bead-shaped materials, ion-exchange resins are also produced as membranes. These ion-exchange membranes, which are made of highly cross-linked ion-exchange resins that allow passage of ions, but not of water, are used for electrodialysis. Four main types of ion-exchange resins differ in their functional groups:
dispersion A system in which particles of one material are distributed within a continuous phase of another material; the two phases may be in the same or different states of matter. Dispersions of particles sufficiently large for sedimentation are called suspensions, while those of smaller particles are called colloids or solutions.
The cyclol fabric was shown to be implausible for several reasons. Hans Neurath and Henry Bull showed that the dense packing of side chains in the cyclol fabric was inconsistent with the experimental density observed in protein films. Maurice Huggins calculated that several non-bonded atoms of the cyclol fabric would approach more closely than allowed by their van der Waals radii; for example, the inner Hα and Cα atoms of the lacunae would be separated by only 1.68 Å (Figure 5). Haurowitz showed chemically that the outside of proteins could not have a large number of hydroxyl groups, a key prediction of the cyclol model, whereas Meyer and Hohenemser showed that cyclol condensations of amino acids did not exist even in minute quantities as a transition state. More general chemical arguments against the cyclol model were given by Bergmann and Niemann and by Neuberger. Infrared spectroscopic data showed that the number of carbonyl groups in a protein did not change upon hydrolysis, and that intact, folded proteins have a full complement of amide carbonyl groups; both observations contradict the cyclol hypothesis that such carbonyls are converted to hydroxyl groups in folded proteins. Finally, proteins were known to contain proline in significant quantities (typically 5%); since proline lacks the amide hydrogen and its nitrogen already forms three covalent bonds, proline seems incapable of the cyclol reaction and of being incorporated into a cyclol fabric. An encyclopedic summary of the chemical and structural evidence against the cyclol model was given by Pauling and Niemann.
=== Phase 3 === Lysergic acid diethylamide (LSD; lysergide; MM-120; MM120) – non-selective serotonin receptor agonist and psychedelic hallucinogen [1] Ranquilon (6-phenylhexanoyl)glycyl-L-tryptophan amide; GB-115) – cholecystokinin (CCK) receptor antagonist [2] Soclenicant (BNC-210; BNC210; IW-2143; L-isoleucyl-L-tryptophan) – α7-nicotinic acetylcholine receptor negative allosteric modulator [3]
Sources: en.wikipedia.org
Reverse-phase high-performance liquid chromatography with ultraviolet detection is the usual choice, with results reported as area percent. Complementary methods such as size-exclusion chromatography and mass spectrometry are needed because a single separation cannot resolve every impurity class. Purity figures are therefore method dependent and should always be read alongside the technique used.
Oxidation mainly affects methionine residues and is promoted by dissolved oxygen, trace transition metals, and prolonged exposure to light. Buffer choice and the presence of antioxidants in a formulation can alter the rate appreciably. Because the products differ in mass by only a few units, mass spectrometry is often required to detect them.
Published data on long-term ambient stability are limited, so the question remains open rather than settled. Short excursions during transport are common in practice, and many suppliers use insulated packaging with cold packs. Where stability data are absent, cold-chain handling with temperature logging is the safer approach.
差别集中在三处：第 8 位残基被非天然氨基酸取代，第 34 位换成精氨酸，第 26 位增加一条脂肪酸侧链。前两处改动降低酶解速率，侧链则通过白蛋白结合延长循环时间。综合结果是半衰期从约两分钟延长到约一周。